Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

References

1. 1.↵
   2. Torre LA,
   3. Bray F,
   4. Siegel RL,
   5. Ferlay J,
   6. Lortet-Tieulent J,
   7. Jemal A.

   Global cancer statistics, 2012. Ca-Cancer J Clin. 2015; 65: 87–108.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Gainor JF,
   3. Varghese AM,
   4. Ou SHI,
   5. Kabraji S,
   6. Awad MM,
   7. Katayama R, et al.

   ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19: 4273–81.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Zheng DF,
   3. Wang R,
   4. Ye T,
   5. Yu S,
   6. Hu HC,
   7. Shen XX, et al.

   MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget. 2016; 7: 41691–702.

   OpenUrl
4. 4.↵
   2. Shea M,
   3. Costa DB,
   4. Rangachari D.

   Management of advanced non-small cell lung cancers with known mutations or rearrangements: Latest evidence and treatment approaches. Ther Adv Respir Dis. 2016; 10: 113–29.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Roberts PJ,
   3. Stinchcombe TE.

   KRAS mutation: Should we test for it, and does it matter? J Clin Oncol. 2013; 31: 1112–21.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Del Re M,
   3. Tiseo M,
   4. Bordi P,
   5. D’Incecco A,
   6. Camerini A,
   7. Petrini I, et al.

   Contribution of KRAS mutations and c.2369c > t (p.T790m) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA. Oncotarget. 2017; 8: 13611–9.

   OpenUrlCrossRef
7. 7.↵
   2. Eser S,
   3. Schnieke A,
   4. Schneider G,
   5. Saur D.

   Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014; 111: 817–22.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Stjernström A,
   3. Karlsson C,
   4. Fernandez OJ,
   5. Söderkvist P,
   6. Karlsson MG,
   7. Thunell LK.

   Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 2014; 3: 337–48.

   OpenUrl
9. 9.↵
   2. Engelman JA,
   3. Mukohara T,
   4. Zejnullahu K,
   5. Lifshits E,
   6. Borrás AM,
   7. Gale CM, et al.

   Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006; 116: 2695–706.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Liu XL,
    3. Xu YC,
    4. Wang YX,
    5. Chen Y,
    6. Wang BB,
    7. Wang Y, et al.

    Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Ka-selective inhibitor CYH33 in breast cancer. Cancer Lett. 2018; 433: 273–82.

    OpenUrl
11. 11.↵
    2. Shi JJ,
    3. Chen SM,
    4. Guo CL,
    5. Li YX,
    6. Ding J,
    7. Meng LH.

    The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacol Sin. 2018; 39: 1338–46.

    OpenUrl
12. 12.↵
    2. Li X,
    3. Tong LJ,
    4. Ding J,
    5. Meng LH.

    Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett. 2014; 342: 159–66.

    OpenUrl
13. 13.↵
    2. Liu YX,
    3. Qing LH,
    4. Meng CS,
    5. Shi JJ,
    6. Yang Y,
    7. Wang ZW, et al.

    6-oh-phenanthroquinolizidine alkaloid and its derivatives exert potent anticancer activity by delaying s phase progression. J Med Chem. 2017; 60: 2764–79.

    OpenUrl
14. 14.↵
    2. Chou TC.

    Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010; 70: 440–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Watanabe T,
    3. Naito M,
    4. Kokubu N,
    5. Tsuruo T.

    Regression of established tumors expressing p-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst. 1997; 89: 512–8.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Repasky GA,
    3. Chenette EJ,
    4. Der CJ.

    Renewing the conspiracy theory debate: Does raf function alone to mediate ras oncogenesis? Trends Cell Biol. 2004; 14: 639–47.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    2. Barlesi F,
    3. Mazieres J,
    4. Merlio JP,
    5. Debieuvre D,
    6. Mosser J,
    7. Lena H, et al.

    Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016; 387: 1415–26.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Elkabets M,
    3. Vora S,
    4. Juric D,
    5. Morse N,
    6. Mino-Kenudson M,
    7. Muranen T, et al.

    mTORC1 inhibition is required for sensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med. 2013; 5: 196ra99.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    2. Kato J,
    3. Matsushime H,
    4. Hiebert SW,
    5. Ewen ME,
    6. Sherr CJ.

    Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993; 7: 331–42.

    OpenUrlFREE Full Text
20. 20.↵
    2. Majeed R,
    3. Hussain A,
    4. Sangwan PL,
    5. Chinthakindi PK,
    6. Khan I,
    7. Sharma PR, et al.

    PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3ݠand cyclin D1 and potentially checks cancer cell proliferation. Mol Carcinog. 2016; 55: 964–76.

    OpenUrl
21. 21.↵
    2. Nölting S,
    3. Rentsch J,
    4. Freitag H,
    5. Detjen K,
    6. Briest F,
    7. Möbs M, et al.

    The selective PI3Ka inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS One. 2017; 12: e0182852.
22. 22.↵
    2. Jansen VM,
    3. Bhola NE,
    4. Bauer JA,
    5. Formisano L,
    6. Lee KM,
    7. Hutchinson KE, et al.

    Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017; 77: 2488–99.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    2. Green S,
    3. Trejo CL,
    4. McMahon M.

    PIK3CA^H1047R accelerates and enhances KRAS^G12D-driven lung tumorigenesis. Cancer Res. 2015; 75: 5378–91.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    2. Yamamoto H,
    3. Shigematsu H,
    4. Nomura M,
    5. Lockwood WW,
    6. Sato M,
    7. Okumura N, et al.

    PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008; 68: 6913–21.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    2. Vansteenkiste JF,
    3. Canon JL,
    4. De Braud F,
    5. Grossi F,
    6. De Pas T,
    7. Gray JE, et al.

    Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: Results from the phase II BASALT-1 study. J Thorac Oncol. 2015; 10: 1319–27.

    OpenUrlCrossRefPubMed
26. 26.↵
    2. Vora SR,
    3. Juric D,
    4. Kim N,
    5. Mino-Kenudson M,
    6. Huynh T,
    7. Costa C, et al.

    CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014; 26: 136–49.

    OpenUrlCrossRefPubMed
27. 27.↵
    2. Bonelli MA,
    3. Digiacomo G,
    4. Fumarola C,
    5. Alfieri R,
    6. Quaini F,
    7. Falco A, et al.

    Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017; 19: 637–48.

    OpenUrlCrossRef
28. 28.↵
    2. Shi RS,
    3. Li M,
    4. Raghavan V,
    5. Tam S,
    6. Cabanero M,
    7. Pham NA, et al.

    Targeting the CDK4/6-RB pathway enhances response to PI3K inhibition in PIK3CA-mutant lung squamous cell carcinoma. Clin Cancer Res. 2018; 24: 5990–6000.

    OpenUrlAbstract/FREE Full Text